These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1057 related articles for article (PubMed ID: 29920733)

  • 21. Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.
    Eriksson C; Söderling J; Karlqvist S; Bröms G; Everhov ÅH; Bergemalm D; Ludvigsson JF; ; Olén O; Halfvarson J
    Dig Dis Sci; 2023 Jul; 68(7):3119-3128. PubMed ID: 36929241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety Profile of Anti-tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons.
    Miligkos M; Papamichael K; Vande Casteele N; Mantzaris GJ; Gils A; Levesque BG; Zintzaras E
    Clin Ther; 2016 Jun; 38(6):1342-1358.e6. PubMed ID: 27091732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
    Vuyyuru SK; Nguyen TM; Murad MH; Narula N; Bessissow T; Zou G; McCurdy JD; Peyrin-Biroulet L; Danese S; Ma C; Singh S; Jairath V
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1190-1199.e15. PubMed ID: 38185396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis.
    Hazlewood GS; Rezaie A; Borman M; Panaccione R; Ghosh S; Seow CH; Kuenzig E; Tomlinson G; Siegel CA; Melmed GY; Kaplan GG
    Gastroenterology; 2015 Feb; 148(2):344-54.e5; quiz e14-5. PubMed ID: 25448924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis.
    Barberio B; Gracie DJ; Black CJ; Ford AC
    Gut; 2023 Feb; 72(2):264-274. PubMed ID: 35907636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
    Stidham RW; Lee TC; Higgins PD; Deshpande AR; Sussman DA; Singal AG; Elmunzer BJ; Saini SD; Vijan S; Waljee AK
    Aliment Pharmacol Ther; 2014 Jun; 39(12):1349-62. PubMed ID: 24749763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
    Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
    Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
    Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
    J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.
    Na JE; Park YE; Park J; Kim TO; Lee JH; Park SB; Kim S; Lee SB;
    BMC Gastroenterol; 2024 Sep; 24(1):306. PubMed ID: 39261766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: Systematic review and network meta-analysis.
    Gao J; Nie R; Chen Y; Yang W; Ren Q
    Medicine (Baltimore); 2023 Oct; 102(43):e35689. PubMed ID: 37904440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
    Louis E; Litkiewicz M; Agboton C; Armuzzi A
    United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis.
    Moćko P; Kawalec P; Pilc A
    Pharmacol Rep; 2016 Dec; 68(6):1237-1243. PubMed ID: 27686963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
    Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
    Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Hodgson R; Walton M; Biswas M; Mebrahtu T; Woolacott N
    Pharmacoeconomics; 2018 Apr; 36(4):387-398. PubMed ID: 29192397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.